Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Review Article

An Update on the Treatment Strategy for Non-Small Cell Lung Cancer: A Current Scenario and Future Perspective

In Press, (this is not the final "Version of Record"). Available online 19 February, 2024
Author(s): Rahini Rajendran and Jayanthi Mathaiyan*
Published on: 19 February, 2024

DOI: 10.2174/0115733947276538240129053601

Price: $95

Abstract

Non-small cell lung cancer (NSCLC) is a ubiquitous form of lung cancer. Most patients already have metastasis at the time of diagnosis. Chemotherapy and radiotherapy are widely used to treat the early stages of NSCLC, but cancer relapses are common, and the mortality rate is also high. Hence, there is a definite need for newer and advanced therapies to control the recurrence and metastasis of NSCLC. Many clinical trials are underway, which could improve the current treatment options. Targeted therapy and immunotherapies are increasingly developing to expand the overall survival rate of NSCLC patients. Yet, the continuous mutation in the tumor site, drug resistance, adverse effects, and tumor recurrence pose several challenges to the efficacy of the treatment. Many drugs in phase I and II clinical trials prove significant effectiveness against NSCLC mutations. Combination therapy has shown enhanced progression-free and overall survival rates when compared to monotherapy. Recently, FDA-approved genetically engineered patients’ immune cells and chimeric antigen receptors (CAR) improved T-cells for the treatment of malignancies. This review emphasizes the recent development in the treatment regimen and strategy used for improving the outcomes of NSCLC.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy